EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus

Eduard Vieta iD, Mauricio Tohen iD, Diane McIntosh, Lars Vedel Kessing iD, Martha Sajatovic iD, Roger S McIntyre iD

Bipolar Disorders · 2025-02 · 27 (1) · 7-16

DOI: 10.1111/bdi.13498 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bipolar Disorders, online erschienen am 22.10.2024. Verfasst von Eduard Vieta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain. Hauptthemen laut MEDLINE: Antipsychotic Agents, Bipolar Disorder. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development and Commercialization, H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting injectable antipsychotics (LAIs) are not routinely offered to patients living with bipolar disorder type I (BP‐I), despite widespread evidence that supports their benefits over oral antipsychotics, particularly in early disease.

Methods

A round‐table meeting of psychiatrists convened to discuss barriers and opportunities and provide consensus recommendations around the early use of LAIs for BP‐I.

Results

LAIs are rarely prescribed to treat BP‐I unless a patient has severe symptoms, sub‐optimal adherence to oral antipsychotics, or has experienced multiple relapses. Beyond country‐specific accessibility issues (e.g., healthcare infrastructure and availability/approval status), primary barriers to the effective use of LAIs were identified as attitudinal and knowledge/experience‐based. Direct discussions between healthcare providers and patients about treatment preferences may not occur due to a preconceived notion that patients prefer oral antipsychotics. Moreover, as LAIs have historically been limited to the treatment of schizophrenia and the most severe cases of BP‐I, healthcare providers might be unaware of the benefits LAIs provide in the overall management of BP‐I. Improved treatment adherence associated with LAIs compared to oral antipsychotics may support improved outcomes for patients (e.g., reduced relapse and hospitalization). Involvement of all stakeholders (healthcare providers, patients, and their supporters) participating in the patient journey is critical in early and shared decision‐making processes. Clinical and database studies could potentially bridge knowledge gaps to facilitate acceptance of LAIs.

Conclusion

This review discusses the benefits of LAIs in the management of BP‐I and identifies barriers to use, while providing expert consensus recommendations for potential solutions to support informed treatment decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsBipolar DisorderHumansDelayed-Action PreparationsInjections

Stichwörter der Autor:innen

antipsychoticsbipolar disorder type 1consensuspatient‐reported outcome measurespsychosisshared decision‐makingtreatment adherence and compliance

Substanzen

Antipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.
  • Department of Psychiatry and Behavioral Sciences, University of New Mexico Health Science Center, Albuquerque, New Mexico, USA.
  • Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
  • Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Frederiksberg, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.

ORCID-Profile: Eduard Vieta, Mauricio Tohen, Lars Vedel Kessing, Martha Sajatovic, Roger S McIntyre

Förderung

  • Otsuka Pharmaceutical Development and Commercialization
  • H. Lundbeck A/S

Zitieren

APA

Vieta, E., Tohen, M., McIntosh, D., Kessing, L. V., Sajatovic, M., & McIntyre, R. S. (2025). Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus. Bipolar Disorders, 27(1), 7-16. https://doi.org/10.1111/bdi.13498

Vancouver

Vieta E, Tohen M, McIntosh D, Kessing LV, Sajatovic M, McIntyre RS. Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus. Bipolar Disorders. 2025;27(1):7-16. doi:10.1111/bdi.13498

BibTeX
@article{Vieta2025,
  author = {Vieta, Eduard and Tohen, Mauricio and McIntosh, Diane and Kessing, Lars Vedel and Sajatovic, Martha and McIntyre, Roger S},
  title = {Early use of long‐acting injectable antipsychotics in bipolar disorder type I: An expert consensus},
  journal = {Bipolar Disorders},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {7--16},
  doi = {10.1111/bdi.13498}
}
Kostenlos starten →